Comparison study of effect of two concentrations of intra-lesional injection of a drug in patchy hair loss of the scalp
Phase 4
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecified
- Registration Number
- CTRI/2022/11/047692
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients of both sexes(males and females), aged >13 years with AA,
2.Patients having AA on the scalp with <50% involvement.
3.Patients who had not taken any form of treatment in the last 8 weeks.
4.Patients who are willing to sign the written consent form before participating in the study
Exclusion Criteria
1.Patients aged <13 years
2.Patients with alopecia totalis, alopecia universalis and ophiasis.
3.Patients having skin diseases affecting the scalp.
4.Patients with active infection at the local site and with keloidal tendency.
5.Pregnant or lactating women or immuno-compromised patients or patients with bleeding or coagulation disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in Severity Alopecia Tool (SALT) Score, 5 point semi-quantitative Re Growth Scale (RGS) and Dermoscopic AssessmentTimepoint: At Baseline,3 weeks, 6 weeks, 9 weeks,12 weeks
- Secondary Outcome Measures
Name Time Method Assess side effects with two concentrations of intra-lesional injection of triamcinolone acetonideTimepoint: Every 3 weeks then at the 3 months of therapy from baseline (3weeks after the 4th session)